NAFLD is an umbrella term for a variety of illnesses of ranging severity starts with simple steatosis, develops to non-alcoholic steatohepatitis (NASH), then cirrhosis, and if not controlled, eventually can develop to fibrosis and even hepatocellular carcinoma (HCC). The disease is linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM), thus addressing these interconnected disorders could be an effective approach for its management. This review gives an overview the most recent relevant research studies and the on-going therapeutic options for NAFLD focusing on the recently discovered sodium glucose cotransporter 2 inhibitors (SGLT2i), the new antihyperglycemic class of drugs which recently gained adequate popularity, as well as their efficacy and applications in experimental and clinical work.
Heeba, G., Abolnaga, M., & Othman, E. (2023). RECENT APPROACHES FOR SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE. Bulletin of Pharmaceutical Sciences Assiut University, 46(1), 579-595. doi: 10.21608/bfsa.2023.301257
MLA
Gehan H. Heeba; Mohamed Y. Abolnaga; Eman M. Othman. "RECENT APPROACHES FOR SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE". Bulletin of Pharmaceutical Sciences Assiut University, 46, 1, 2023, 579-595. doi: 10.21608/bfsa.2023.301257
HARVARD
Heeba, G., Abolnaga, M., Othman, E. (2023). 'RECENT APPROACHES FOR SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE', Bulletin of Pharmaceutical Sciences Assiut University, 46(1), pp. 579-595. doi: 10.21608/bfsa.2023.301257
VANCOUVER
Heeba, G., Abolnaga, M., Othman, E. RECENT APPROACHES FOR SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE. Bulletin of Pharmaceutical Sciences Assiut University, 2023; 46(1): 579-595. doi: 10.21608/bfsa.2023.301257
)
View on SCiNiTO